Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Immune-metabolic trajectories delineate subgroups in paediatric long COVID.

Nature communications·2026

Same author

Cut or bind? Antigen-specific processing mechanisms define CD4<sup>+</sup> T cell immunodominant epitopes for SARS-CoV-2 S and N proteins.

Genome medicine·2025

Same author

SLAMF7 (CD319) enhances cytotoxic T-cell differentiation and sensitizes CD8<sup>+</sup> T cells to immune checkpoint blockade.

Frontiers in immunology·2025

Same author

PD1<sup>+</sup> innate lymphoid cells 3 predict JAK-dependent inflammation in rheumatoid arthritis.

Journal of autoimmunity·2025

Same author

Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection.

Frontiers in immunology·2025

Same author

SLAMF7 (CD319) on activated CD8<sup>+</sup> T cells transduces environmental cues to initiate cytotoxic effector cell responses.

Cell death and differentiation·2024

Search research articles

Related Experiment Video

Updated: Jan 5, 2026

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

CTLA-4 (CD152): A versatile receptor for immune-based therapy.

Holger Lingel¹, Monika C Brunner-Weinzierl¹

¹Department of Experimental Pediatrics, University Hospital, Health Campus Immunology, Infectiology and Inflammation, Otto-von-Guericke-University Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany.

Seminars in Immunology

|October 13, 2019

Summary

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a key regulator of immune responses and a target for cancer immunotherapy. Further understanding CTLA-4 biology is crucial for improving existing cancer treatments.

Keywords:

Abatacept CTLA-4 Cancer immunotherapy Immune checkpoint Ipilimumab

More Related Videos

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Related Experiment Videos

Last Updated: Jan 5, 2026

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Area of Science:

Immunology
Oncology
Cancer Immunotherapy

Background:

Coreceptor-based immunotherapy is a rapidly advancing cancer treatment strategy.
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a critical attenuator of adaptive immune responses.
CTLA-4 plays a significant role in regulating immune cell functions, offering therapeutic intervention possibilities.

Purpose of the Study:

To review the diverse functions of CTLA-4.
To examine CTLA-4-based immunotherapies.
To discuss challenges and potential improvements for current CTLA-4-targeted approaches.

Main Methods:

Literature review of CTLA-4 functions.
Analysis of clinical data for CTLA-4-based immunotherapies.
Discussion of unresolved aspects of CTLA-4 biology.

Main Results:

CTLA-4 is a prominent and extensively studied molecule in cancer immunotherapy.
CTLA-4 is successfully utilized in clinical treatments.
Despite clinical success, the complete biology of CTLA-4 remains incompletely understood.

Conclusions:

CTLA-4-based immunotherapies represent a promising area in cancer treatment.
Further research into CTLA-4 functions is needed to optimize therapeutic strategies.
Addressing the gaps in understanding CTLA-4 biology will enhance its clinical application.